Slide 1: Earnings Call – Q3 2022
Earnings Call – Q3 2022 November 1, 2022 Exhibit 99.2
Slide 2: Forward-looking statement
2©2022 ViewRay Technologies, Inc. All rights reserved. Forward-looking statement This presentation contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this presentation that are not purely historical are forward-looking
Slide 3: What we achieved – financial results Q3 2022
3©2022 ViewRay Technologies, Inc. All rights reserved. What we achieved – financial results Q3 2022 Q3 2022 Q3 2021 Change MRIdian orders 8 7 14% MRIdian backlog $370.5M $295.1M 26% Revenue $26.5M $19.2M 38% Gross Margin 16.8% 9.9% +690 bps Cash use $15.3M $17.0M ($1.7m)
Slide 4: LAP-ABLATE Phase III pancreatic cancer study
4©2022 ViewRay Technologies, Inc. All rights reserved. • Phase 3 • Global • Multi-center • RCT • 267 patients • 2 year Overall survival primary endpoint Enrollment to begin in 2023 Study design Patient enrollment begins in 2023 GROUNDING FACTORS • Conventional RT has failed to show a survival benefi
Slide 5: MRIdian well positioned to improve outcomes in China
5©2022 ViewRay Technologies, Inc. All rights reserved. MRIdian Well positioned to improve outcomes in China LUNG LIVER PROSTATEPANCREASBREAST #1 type + cause of cancer death in China #3 cause of cancer death in China #4 most common type of cancer in China #6 cause of cancer death in China #11 most c
Slide 6: MRIdian
_ a SMRidianasi
Slide 7: Financial results Q3 2022
> vIEWRAY Financial results Q3 2022
Slide 8: Q3 2022 results
8©2022 ViewRay Technologies, Inc. All rights reserved. Revenue increased 38% - 4 units vs 3 units in the prior year - 100% service attachment Gross margin improved to 17% - Product gross margin 19% - Service gross margin 5% Operating expenses control - R&D down 3% - S&M up 71% - G&A up 3% Cash use o
Slide 9: 2022 guidance
9©2022 ViewRay Technologies, Inc. All rights reserved. 2022 guidance Current Prior Revenue $94M ‒ $104M $90M ‒ $104M Growth 34% ‒ 48% 28% ‒ 48% Cash usage $78M ‒ $92M $68M ‒ $83M
Slide 10: Delivering P&L leverage '22 and beyond
10©2022 ViewRay Technologies, Inc. All rights reserved. Delivering P&L leverage ‘22 and beyond Meaningful operating expense leverage… 2.3x YTD On track to deliver ~40% revenue growth… 36% YTD Well capitalized: sufficiently capitalized to drive to cash flow breakeven In 2022… Placements expected to d
Slide 11: ViewRay Investor Day
11©2022 ViewRay Technologies, Inc. All rights reserved. ViewRay Investor Day Intercontinental Hotel New York, NY November 17, 2022
Slide 12: ViewRay | Visibly Better
@ VIEW RAY | VISIBLY BETTER
Slide 13: References
13©2022 ViewRay Technologies, Inc. All rights reserved. References 1Rudra S. et al. (2019). Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Medicine, 8(5), 2123-2132. 2Chen A. M. et al. (2018). MRI-guided radiotherapy for head an